Related Experiment Video
Updated: May 31, 2026
12:30
Avidity-based Extracellular Interaction Screening (AVEXIS) for the Scalable Detection of Low-affinity Extracellular Receptor-Ligand Interactions
Published on: March 5, 2012
Biolayer interferometry-based detection of engineered extracellular vesicles binding to type I collagen
Yan-Jing Zhang1, Yinchan Wang1, Xuemei Chen1
1Core Facility of West China Hospital, West China Hospital, Sichuan University, 37 Guoxue Alley, Chengdu, 610041, China.
Analytical Biochemistry
|May 29, 2026
Summary
Researchers developed a new biolayer interferometry (BLI) platform to monitor engineered extracellular vesicles (EVs) interacting with collagen. This method enhances the development of targeted EV therapeutics by quantifying EV-collagen binding kinetics.
Area of Science:
- Biotechnology
- Nanomedicine
- Materials Science
Background:
- Engineered extracellular vesicles (EVs) show promise as therapeutic agents and drug delivery systems.
- Real-time monitoring of EV-target interactions is crucial for advancing EV-based therapeutics.
- Current methods lack the precision for dynamic interaction analysis.
Purpose of the Study:
- To develop a novel analytical platform for detecting dynamic interactions between engineered EVs and their molecular targets.
- To establish a method for quantifying the binding kinetics of collagen-binding domain (CBD)-engineered EVs to type I collagen (Col I).
Main Methods:
- Engineered EVs (TT-D6sCBD-EVs) were produced from a stable CD63-CBD fusion protein-expressing cell line.
- Type I collagen (Col I) was immobilized on AR2G biosensors for detection via biolayer interferometry (BLI).
- EV binding was quantified using BLI and validated with scanning electron microscopy (SEM) and confocal microscopy.
Main Results:
- TT-D6sCBD-EVs demonstrated significantly enhanced BLI signals compared to control EVs (TT-D6sVec-EVs).
- Time-dependent signal accumulation indicated stable and dynamic binding of engineered EVs to Col I.
- Microscopy confirmed increased binding capacity of engineered EVs.
Conclusions:
- A novel BLI-based platform was established for characterizing engineered EV-target interactions.
- This methodology provides critical technical support for advancing precision EV-based therapeutics.
- The platform enables quantitative analysis of binding kinetics, facilitating the development of targeted therapies.
